BIVV003
Sickle Cell Disease
Phase 1/2Active (PRECIZN-1 Study)
Key Facts
Indication
Sickle Cell Disease
Phase
Phase 1/2
Status
Active (PRECIZN-1 Study)
Company
About Sangamo Therapeutics
Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.
View full company profileOther Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Decitabine combination | Novo Nordisk | Phase 2 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 |
| DISC-3405 | Disc Medicine | Phase 1 |
| Mitapivat | Agios Pharmaceuticals | Phase 2/3 |
| FTX-6058 | Fulcrum Therapeutics | Phase 1b |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| CT-101 | Cetya Therapeutics | Pre-clinical |